Virtual Reality Cognitive Therapy forAlzheimer's Disease

阿尔茨海默病的虚拟现实认知疗法

基本信息

批准号：
10768289
负责人：
Razi Masood
金额：
$ 5.5万
依托单位：
CLARITYTEK, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-30 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10768289
关键词：
Activities of Daily Living Affect Alzheimer&apos s Disease Alzheimer&apos s disease patient Alzheimer&apos s disease related dementia American COVID-19 COVID-19 pandemic Cognitive Cognitive Therapy Cognitive aging Cognitive deficits Consultations Disease Equipment Evaluation Exposure to Face Family Feedback Focus Groups Guidelines Health Impaired cognition Individual International Intervention Life Methods Names Neurosciences Nursing Homes Outcome Participant Patient Education Patients Pharmaceutical Preparations Quality of life Research Resource-limited setting Self Management Social Distance Societies Specialist System Testing Training Activity Underserved Population United States Work cohort cost design digital health digital intervention digital treatment disability impact distraction empowerment evidence base functional independence health related quality of life improved innovation instrumental activity of daily living medical appointment multidisciplinary novel patient response preservation public health relevance remediation satisfaction skills success therapy development tool treatment response usability virtual reality

项目摘要

ABSTRACT Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) currently affect more than 5.8 million Americans, costing $305 billion for treatment and management in 2020 and causing poor outcomes such as loss of independence, low quality of life, and nursing home requirements. Given the scale of diminished health-related quality of life, the need for non-invasive customizable cognitive impairment (CI) targeting methods to assist AD patients is imperative. There is a significant need for effective individualized digital interventions for AD patients accessible with social distancing in the COVID-19 pandemic situation. Claritytek proposes to develop an evidence-based, non-invasive, novel tool targeting individual aging cognitive deficits to improve AD/ADRD patients' quality of life. Virtual Reality Cognitive Therapy (VRCT) utilizes a four- pronged approach: Assess, Educate, Treat, and Track. VR is immersive, isolating the patient from surrounding distractions -- crucial for any CI intervention. Cognitive Interventions for AD should consider all facets of cognitive deficits, especially skills impacting activities of daily living (ADL) and IADL (instrumental ADL). VRCT aims to treat IADL disabilities impacting AD patients. VRCT training activities are designed to imitate real-life situations, tailored to engage, adapt, challenge, simulating lifelike CI-producing scenarios in contexts where they occur. Utilizing VRCT, repeated exposures to CI scenarios through game loops to gradually train patients in useful skills: medical appointments, taking medications, shopping, and remembering names, faces, and directions to places – to preserve and improve functional independence. Our system will include an optional mode for asynchronous online therapist consultations without face-to-face contact, valuable during COVID-19 isolations. We will expand, adapt, and build on our team’s prior successful work for Alzheimer’s patients with CI, ranked among the top 5 innovations in the world at an international digital health competition. We will partner with specialists at the HealthPartners Neuroscience Center for Alzheimer’s Research to lead the trial and help design, develop, and optimize VRCT. We will incorporate stakeholder feedback to create a patient-centric intervention targeting four specific prioritized "CI" related to IADL, utilizing guidelines of the digital therapy development frameworks. To guide the project, we will create a multidisciplinary Expert Focus Group (EFG). In Aim 1, we will evaluate the feasibility, usability, and acceptability of VRCT on 36 AD/ADRD patients with mild to moderate CI over seven weeks. We will conduct three trials, each trial with a cohort of n=12, total of n=36 participants. In addition to the patient’s responses to the therapy, a focus of the evaluation will be cognitive tolerability, as the target patients have CI. The results from each trial will be applied iteratively in Aim 2 to revise the VRCT before the next trial, producing the most acceptable CI intervention. In Aim 2, we will iteratively redesign, develop, unit test, and optimize VRCT based on patients’ feedback from the trials and EFG analysis. We expect to establish that VRCT will be feasible, usable, and acceptable with a Usability Scale success rate of 90%, and user satisfaction of 80%.

抽象的阿尔茨海默病 (AD) 和阿尔茨海默病相关痴呆 (ADRD) 目前影响超过 5.8 百万美国人，到 2020 年将花费 3050 亿美元用于治疗和管理，并造成不良后果，例如由于丧失独立性、生活质量低以及疗养院需求规模缩小。健康相关的生活质量，需要非侵入性可定制的认知障碍（CI）靶向方法帮助AD患者势在必行，迫切需要有效的个性化数字干预措施。在 COVID-19 大流行情况下，AD 患者可以在保持社交距离的情况下进行接触。 Claritytek 提议开发一种针对个人衰老认知的循证、非侵入性新型工具虚拟现实认知疗法 (VRCT) 利用四项功能来改善 AD/ADRD 患者的生活质量。多管齐下：评估、教育、治疗和跟踪 VR 是身临其境的，将患者与周围环境隔离开来。干扰——对于 AD 的任何 CI 干预都至关重要，应考虑认知的所有方面。缺陷，特别是影响日常生活活动 (ADL) 和 IADL（工具性 ADL）的技能。治疗影响 AD 患者的 IADL 残疾 VRCT 培训活动旨在模仿现实生活情况，专为参与、适应、挑战、模拟逼真的 CI 生成场景而设计。利用 VRCT，通过游戏循环反复接触 CI 场景，逐步训练患者掌握有用的知识技能：医疗预约、服药、购物以及记住姓名、面孔和方向地方 - 保持和提高功能独立性我们的系统将包括一个可选模式。无需面对面接触的异步在线治疗师咨询，在 COVID-19 隔离期间非常有价值。我们将扩展、调整和发展我们团队之前针对患有 CI 的阿尔茨海默氏症患者的成功工作，排名在国际数字健康竞赛中跻身世界前 5 名创新之列。我们将与 HealthPartners 阿尔茨海默病研究神经科学中心的专家合作，领导试验并帮助设计、开发和优化 VRCT。我们将结合利益相关者的反馈来创建。利用 IADL 的指南，针对与 IADL 相关的四个特定优先“CI”进行以患者为中心的干预为了指导该项目，我们将创建一个多学科专家焦点。集团（EFG）。在目标 1 中，我们将评估 VRCT 对 36 名轻度 AD/ADRD 患者的可行性、可用性和可接受性我们将在七周内进行三项试验，每项试验都有一组 n=12，总共 n=36。除了患者对治疗的反应外，评估的重点还将是认知。耐受性，因为目标患者有 CI。每个试验的结果将在目标 2 中迭代应用以进行修订。在下一次试验之前进行 VRCT，产生最可接受的 CI 干预。在目标 2 中，我们将根据患者的反馈迭代地重新设计、开发、单元测试和优化 VRCT 我们期望通过试验和 EFG 分析确定 VRCT 是可行的、可用的和可接受的。可用性量表成功率达90%，用户满意度达80%。